Android app on Google Play

Sequenom (SQNM) MaterniT21 PLUS LDT Now Reporting on Fetal Chromosomal Aneuploidies

February 4, 2013 7:04 AM EST Send to a Friend
Sequenom, Inc. (Nasdaq: SQNM) announced that the MaterniT21 PLUS laboratory-developed test (LDT) available exclusively through Sequenom Center for Molecular Medicine (Sequenom CMM) will now report as additional findings the presence of certain fetal sex chromosomal aneuploidies, in addition to its identification of autosomal aneuploidies for chromosome 21 (associated with Down syndrome), chromosome 18 (associated with Edwards syndrome), and chromosome 13 (associated with Patau syndrome). Reporting of these sex aneuploidies will begin for samples received as of Monday, February 4, 2013.

The test will report on the presence of four rare aneuploidies involving an abnormal number of X or Y chromosomes, including female syndromes 45,X (Turner Syndrome) and 47,XXX (Triple X Syndrome), and male syndromes 47,XXY (Klinefelter Syndrome) and 47,XYY. Results of the blinded clinical validation study set have been submitted for publication in a peer-reviewed journal.




You May Also Be Interested In


Related Categories

Corporate News, FDA

Add Your Comment